Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe 30 mg added to ongoing ezetimibe 10 mg in homozygous sitosterolemia
2004-001580-22Phase 3Completed
- Sponsor
- MSD
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sitosterolemia comparing Ezetrol 10 mg + Ezetrol 30 mg with Ezetrol 10 mg + placebo (2 arms). Primary endpoints: Plasma sitosterol concentration, Plasma campesterol concentration and 6 more. Started Oct 2004; status: completed.
02
Drugs
ezetimibe
03
Conditions
sitosterolemia
Beyond the preview
Go deeper on 2004-001580-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001580-22.